EC
ESPR icon

EntryPoint Capital’s Esperion Therapeutics ESPR Stock Holding History

EntryPoint Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,500
Closed -$64.4K – 842
2026
Q1 		$64.4K Hold
23,500
– – 0.02% 720
2025
Q4 		$87K Buy
+23,500
New +$75.9K 0.03% 612

Other funds holding ESPR

Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Arbitrage
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

EntryPoint Capital's ESPR Position: Q2 2026 in Review

EntryPoint Capital sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 23,500 shares — an estimated $64.4K sold.

EntryPoint Capital first reported a position in ESPR in Q4 2025 and held it in 2 quarters. The position peaked at $87K in Q4 2025. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • EntryPoint Capital reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • EntryPoint Capital sold 23,500 Esperion Therapeutics shares in Q2 2026, an estimated $64.4K.
  • EntryPoint Capital first reported a position in Esperion Therapeutics in Q4 2025 and held it in 2 quarters.
  • EntryPoint Capital's Esperion Therapeutics position peaked at $87K in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.